Measurement of endocrine activity (SET2,3) related to prognosis and prediction of benefit from dose-dense (DD) chemotherapy in estrogen receptor-positive (ER+) cancer: CALGB 9741 (Alliance).
Abstract:505 Background: We investigated the clinical utility of SET2,3, a novel biomarker designed to measure to endocrine sensitivity. SET2,3 measures nonproliferative hormone receptor-related transcription (SETER/PR) adjusted for a baseline prognosis index derived from tumor size, nodes involved and a 4-gene molecular subtype (RNA4). CALGB 9471 is a seminal phase III study that showed improved DFS and OS from 2-weekly dose-dense (DD) vs 3-weekly chemotherapy in ER-negative cancers. Risk of recurrence (ROR-PT) score… Show more
“…We expect such an approach to be promising as evidenced from a recently reported analysis of the phase 3 CALGB9741 (Alliance) trial. Here, the investigators discovered that expression of SET2,3, a biomarker of endocrine sensitivity, could have prognostic and predictive potential for the use of ddCTX in pre‐and postmenopausal women with ER‐positive cancer [ 49 ].…”
“…We expect such an approach to be promising as evidenced from a recently reported analysis of the phase 3 CALGB9741 (Alliance) trial. Here, the investigators discovered that expression of SET2,3, a biomarker of endocrine sensitivity, could have prognostic and predictive potential for the use of ddCTX in pre‐and postmenopausal women with ER‐positive cancer [ 49 ].…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.